NCT02331134View on ClinicalTrials.gov

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 13, 2015

Primary Completion Date

July 6, 2018

Study Completion Date

March 6, 2025

Conditions
Malignant MelanomaHead and Neck Cancer
Interventions
DRUG

Filgrastim

Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
collaborator

Karsh Family Research Fund

OTHER

lead

University of Colorado, Denver

OTHER

NCT02331134 - Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer | Biotech Hunter | Biotech Hunter